计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| F138016-10mg |
10mg |
现货 ![]() |
| |
| F138016-100mg |
100mg |
现货 ![]() |
| |
| F138016-50mg |
50mg |
现货 ![]() |
| |
| F138016-500mg |
500mg |
期货 ![]() |
| |
| F138016-250mg |
250mg |
期货 ![]() |
| |
| F138016-1g |
1g |
现货 ![]() |
|
| 别名 | FK-506一水合物 | FK-506 一水合物 | 他克莫司 一水合物 | 藤霉素一水合物 |
|---|---|
| 英文别名 | D00107 | Tacrolimus, Pharmaceutical Secondary Standard; Certified Reference Material | TACROLIMUS [USP-RS] | TACROLIMUS MONOHYDRATE [WHO-DD] | FK 506 | TACROLIMUS [ORANGE BOOK] | TACROLIMUS MONOHYDRATE | WM0HAQ4WNM | FK-506 monohydrate, >=98% (HPLC) | Pro |
| 规格或纯度 | ≥80%(HPLC) |
| 英文名称 | Tacrolimus Monohydrate |
| 生化机理 | 它是一种强效免疫抑制剂、神经保护剂和神经再生剂,也是体外 T 细胞增殖阻断剂。FK-506 可破坏 T 淋巴细胞中钙调素介导的信号转导,并与其 FK-506 结合蛋白-12(FKBP12)相互作用。 |
| 储存温度 | 避光,-20°C储存,充氩 |
| 运输条件 | 超低温冰袋运输 |
| 产品介绍 |
Tacrolimus monohydrate (FK506 monohydrate) 是大环内酯类化合物,Tacrolimus monohydrate 与 FK506 结合蛋白 (FKBP) 结合形成复合物并抑制钙调神经磷酸酶 (calcineurin phosphatase),从而抑制 T 淋巴细胞信号转导和 IL-2 转录。具有强免疫抑制特性。 Application FK-506 monohydrate has been used: as an immunosuppressive agent in coculture medium to study the effect of immunologic reaction as a calcineurin inhibitor, in anhydrous Me2SO solution to treat retinal pigment epithelial cells to measure possible cytotoxicity |
| 纯度 | ≥80%(HPLC) |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504763414 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-[(E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-13,19,21,27-tetramethyl-17-prop-2-enyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone;hydrate |
| INCHI | 1S/C44H69NO12.H2O/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7;/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3;1H2/b25-19+,27-21+;/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+;/m0./s1 |
| InChi Key | NWJQLQGQZSIBAF-MLAUYUEBSA-N |
| Smiles | CC1CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C(CC(=O)C(C=C(C1)C)CC=C)O)C)C(=CC4CCC(C(C4)OC)O)C)O)C)OC)OC.O |
| Isomeric SMILES | C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC.O |
| 分子量 | 822.03 |
| Reaxy-Rn | 43416939 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=43416939&ln= |
| 溶解性 | Soluble in 20 mg/mL of DMSO |
|---|---|
| 敏感性 | 对光线和热敏感 |
| 熔点 | 127 °C |
| 分子量 | 822.000 g/mol |
| XLogP3 | |
| 氢键供体数Hydrogen Bond Donor Count | 4 |
| 氢键受体数Hydrogen Bond Acceptor Count | 13 |
| 可旋转键计数Rotatable Bond Count | 7 |
| 精确质量Exact Mass | 821.493 Da |
| 单同位素质量Monoisotopic Mass | 821.493 Da |
| 拓扑极表面积Topological Polar Surface Area | 179.000 Ų |
| 重原子数Heavy Atom Count | 58 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 1480.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 14 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 2 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 2 |
| 共价键合单元计数Covalently-Bonded Unit Count | 2 |
| 象形图 | GHS06 |
|---|---|
| 信号词 | 危险 |
| 危险声明 |
H301: 吞咽会中毒 |
| 预防措施声明 |
P264: 处理后要彻底洗手。 P270: 使用本产品时,请勿进食、饮水或吸烟。 P321: 特殊处理(请参阅此标签上的...)。 P330: 漱口 P405: 密闭存放 P501: 将内容物/容器处理到。。。 P301+P316: 如果吞咽:立即寻求紧急医疗救助。 |
| WGK Germany | 3 |
| RTECS | KD4201200 |
| Merck Index | 9025 |
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | F138016 | |
| 分析证书 | F138016 | |
| 分析证书 | F138016 | |
| 分析证书 | F138016 | |
| 分析证书 | F138016 | |
| 分析证书 | F138016 | |
| 分析证书 | F138016 | |
| 分析证书 | F138016 | |
| 分析证书 | F138016 | |
| 分析证书 | F138016 | |
| 分析证书 | F138016 |
| 1. Feng Chen, Xiaoxia Yang, Huanhuan Li, Xiaodan Zeng, Ziwei Deng, Hongqiang Wang, Yuanxiang Jin, Chengfeng Qiu, Zhihua Shi. (2023) Improved LC–MS/MS method for the simultaneous quantification of tacrolimus and cyclosporine A in human blood and application to therapeutic drug monitoring. BIOMEDICAL CHROMATOGRAPHY, 37 (12): (e5751). [PMID:37772369] [10.1002/bmc.5751] |
| 2. Xiaoqian Jiang, Xinxin Xu, Hua Kuang, Liqiang Liu, Liguang Xu, Aihua Qu, Chuanlai Xu. (2023) A gold-based immunochromatographic strip for the specific detection of tacrolimus in whole blood. Journal of Materials Chemistry B, 11 (20): (4464-4474). [PMID:37159048] [10.1039/D3TB00569K] |
| 3. Fei Gong, Huihui Hu, Ying Ouyang, Zheng-Zheng Liao, Ying Kong, Jin-Fang Hu, Hua He, Ying Zhou. (2023) Physiologically-based pharmacokinetic modeling-guided rational combination of tacrolimus and voriconazole in patients with different CYP3A5 and CYP2C19 alleles. TOXICOLOGY AND APPLIED PHARMACOLOGY, 466 (116475). [PMID:36931438] [10.1016/j.taap.2023.116475] |
| 4. Wang Hongkang, Ji Zhe, Feng Yanru, Yan Tianhua, Cao Yongbing, Lu Hui, Jiang Yuanying. (2022) Myriocin enhances the antifungal activity of fluconazole by blocking the membrane localization of the efflux pump Cdr1. Frontiers in Pharmacology, 13 [PMID:36618949] [10.3389/fphar.2022.1101553] |
| 5. Qingfeng He, Fengjiao Bu, Qizhen Wang, Min Li, Jiaying Lin, Zhijia Tang, Wen Yao Mak, Xiaomei Zhuang, Xiao Zhu, Hai-Shu Lin, Xiaoqiang Xiang. (2022) Examination of the Impact of CYP3A4/5 on Drug–Drug Interaction between Schizandrol A/Schizandrol B and Tacrolimus (FK-506): A Physiologically Based Pharmacokinetic Modeling Approach. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 23 (9): (4485). [PMID:35562875] [10.3390/ijms23094485] |
| 6. Gao Ping, Du Xiaoyi, Liu Lili, Xu Hua, Liu Maochang, Guan Xinlei, Zhang Chengliang. (2021) Astragaloside IV Alleviates Tacrolimus-Induced Chronic Nephrotoxicity via p62-Keap1-Nrf2 Pathway. Frontiers in Pharmacology, 11 [PMID:33536919] [10.3389/fphar.2020.610102] |
| 7. Y. Chen, Y. Yang, F. Wang, X. Yang, F. Yao, K. Ming, W. Yuan, L. Zeng, J. Liu. (2018) Antiviral effect of baicalin phospholipid complex against duck hepatitis A virus type 1. POULTRY SCIENCE, 97 (2722). [PMID:29757435] [10.3382/ps/pey155] |
| 8. Hongyan Zhang, Fengjiao Bu, Lei Li, Zheng Jiao, Guo Ma, Weimin Cai, Xiaomei Zhuang, Hai-Shu Lin, Jae-Gook Shin, Xiaoqiang Xiang. (2017) Prediction of Drug–Drug Interaction between Tacrolimus and Principal Ingredients of Wuzhi Capsule in Chinese Healthy Volunteers Using Physiologically-Based Pharmacokinetic Modelling. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 122 (3): (331-340). [PMID:28945011] [10.1111/bcpt.12914] |
| 9. Xinhang Meng, Minfeng Shi, Jinfeng Qian, Yujie Luo, Liyuan Cui, Dajin Li, Songcun Wang. (2025) Tacrolimus (FK506) promotes placentation and maternal-fetal tolerance through modulating FASN-CEACAM1 pathway. Frontiers in Immunology, 16 (1522346). [PMID:40046057] [10.3389/fimmu.2025.1522346] |